Patents by Inventor Rasmus Just

Rasmus Just has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS
    Publication number: 20210363213
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • Glucagon-GLP-1-GIP triple agonist compounds
    Patent number: 11111285
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 7, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • AMYLIN ANALOGUES
    Publication number: 20210115104
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: August 6, 2020
    Publication date: April 22, 2021
    Applicant: Zealand Pharma A/S
    Inventors: Rasmus JUST, Oliver DEMMER, Lise GIEHM, Jesper Skodborg VILLADSEN, Henrik MUNCH, Jesper Mosolff MATHIESEN, Jolanta SKARBALIENE, Maria DERYABINA, Dieter Wolfgang HAMPRECHT
  • Amylin analogues
    Patent number: 10766939
    Abstract: The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 8, 2020
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Oliver Demmer, Lise Giehm, Jesper Sloth Villadsen, Henrik Munch, Jesper Mosolff Mathiesen, Jolanta Skarbaliene, Maria Deryabina, Dieter Wolfgang Hamprecht
  • GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS
    Publication number: 20190270789
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Application
    Filed: October 4, 2018
    Publication date: September 5, 2019
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS
    Publication number: 20190135886
    Abstract: The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
    Type: Application
    Filed: September 5, 2018
    Publication date: May 9, 2019
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • Glucagon analogues
    Patent number: 10253081
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 9, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • Glucagon-like-peptide-2 (GLP-2) analogues
    Patent number: 10253080
    Abstract: GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: April 9, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Kirsten Lindegaard Bovbjerg, Ditte Riber, Wayne Shaun Russell
  • GLUCAGON ANALOGUES
    Publication number: 20190055296
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 18, 2018
    Publication date: February 21, 2019
    Inventors: Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
  • Glucagon-GLP-1-GIP triple agonist compounds
    Patent number: 10131702
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 20, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
    Publication number: 20180298077
    Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Application
    Filed: April 11, 2018
    Publication date: October 18, 2018
    Inventors: Rasmus JUST, Kirsten Lindegaard BOVBJERG, Ditte RIBER, Wayne Shaun RUSSELL
  • GIP-GLP-1 dual agonist compounds and methods
    Patent number: 10100097
    Abstract: The present invention relates to truncated GIP analogs which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: October 16, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • Glucagon analogues
    Patent number: 9975939
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: May 22, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • Glucagon-like-peptide-2 (GLP-2) analogues
    Patent number: 9969787
    Abstract: GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: May 15, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Kirsten Lindegaard Bovbjerg, Ditte Riber, Wayne Shaun Russell
  • GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
    Publication number: 20160355563
    Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Application
    Filed: August 16, 2016
    Publication date: December 8, 2016
    Inventors: Rasmus JUST, Kirsten Lindegaard BOVBJERG, Ditte RIBER, Wayne Shaun RUSSELL
  • Glucagon-like-peptide-2 (GLP-2) analogues
    Patent number: 9453064
    Abstract: GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis, treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: September 27, 2016
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Kirsten Lindegaard Bovbjerg, Ditte Riber, Wayne Shaun Russell
  • AMYLIN ANALOGUES
    Publication number: 20160272693
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: March 18, 2016
    Publication date: September 22, 2016
    Inventors: Rasmus JUST, Oliver DEMMER, Lise GIEHM, Jesper Sloth VILLADSEN, Henrik MUNCH, Jesper Mosolff MATHIESEN, Jolanta SKARBALIENE, Maria DERYABINA, Dieter Wolfgang HAMPRECHT
  • GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS
    Publication number: 20160257729
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Application
    Filed: November 6, 2014
    Publication date: September 8, 2016
    Applicant: Zealand Pharma A/S
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torbenä ØSTERLUND, Kate HANSEN, Lene JESSEN
  • GLUCAGON ANALOGUES
    Publication number: 20160009777
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 24, 2015
    Publication date: January 14, 2016
    Inventors: Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
  • Glucagon analogues
    Patent number: 9180169
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: November 10, 2015
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist